Review





Similar Products

200 suspension chip multiplex detection system utilizes bead based dual fluorescence labeling  (DiaSorin Biotechnology)
99
DiaSorin Biotechnology 200 suspension chip multiplex detection system utilizes bead based dual fluorescence labeling
200 Suspension Chip Multiplex Detection System Utilizes Bead Based Dual Fluorescence Labeling, supplied by DiaSorin Biotechnology, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/utility/Luminex+200+System/10__1007_slash_s10989___026___10866___8-216-2-1
Average 99 stars, based on 1 article reviews
200 suspension chip multiplex detection system utilizes bead based dual fluorescence labeling - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
rna seq utilizes illumina sequencing  (Plasmidsaurus)
99
Plasmidsaurus rna seq utilizes illumina sequencing
Rna Seq Utilizes Illumina Sequencing, supplied by Plasmidsaurus, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/utility/RNA-Seq/pm42595906-538-2-1
Average 99 stars, based on 1 article reviews
rna seq utilizes illumina sequencing - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
pradhan mantri jan arogya yojana increased utilization  (Arogya Inc)
86
Arogya Inc pradhan mantri jan arogya yojana increased utilization
Pradhan Mantri Jan Arogya Yojana Increased Utilization, supplied by Arogya Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/utility/arogya+jan+mantri+pradhan+yojana/pmc13264029-37-9-12
Average 86 stars, based on 1 article reviews
pradhan mantri jan arogya yojana increased utilization - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
immunohistochemical staining utilized pcna  (ABclonal Biotechnology)
93
ABclonal Biotechnology immunohistochemical staining utilized pcna
a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
Immunohistochemical Staining Utilized Pcna, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/utility/PCNA+Mouse+mAb/pmc13526793-823-0-8
Average 93 stars, based on 1 article reviews
immunohistochemical staining utilized pcna - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
quantitative pcr process utilized chamq sybr qpcr master mix  (Vazyme Biotech Co)
99
Vazyme Biotech Co quantitative pcr process utilized chamq sybr qpcr master mix
a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
Quantitative Pcr Process Utilized Chamq Sybr Qpcr Master Mix, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/utility/ChamQ+SYBR+qPCR+Master+Mix/pm41413714-56-1-11
Average 99 stars, based on 1 article reviews
quantitative pcr process utilized chamq sybr qpcr master mix - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
statistical processing utilized graphpad prism 8  (GraphPad Software Inc)
99
GraphPad Software Inc statistical processing utilized graphpad prism 8
a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
Statistical Processing Utilized Graphpad Prism 8, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/utility/Prism+8/pm41980611-142-0-3
Average 99 stars, based on 1 article reviews
statistical processing utilized graphpad prism 8 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
treatment utilized poractant alfa  (Chiesi)
86
Chiesi treatment utilized poractant alfa
a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
Treatment Utilized Poractant Alfa, supplied by Chiesi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/utility/alfa+poractant/pm42316154-71-1-6
Average 86 stars, based on 1 article reviews
treatment utilized poractant alfa - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
utility  (Galectin Therapeutics)
86
Galectin Therapeutics utility
a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
Utility, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/utility/pm42278921-240-3-5
Average 86 stars, based on 1 article reviews
utility - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
resource utilization  (Anhui Medical University)
86
Anhui Medical University resource utilization
a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
Resource Utilization, supplied by Anhui Medical University, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/utility/resource+utilization/pm42265069-30-9-11
Average 86 stars, based on 1 article reviews
resource utilization - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
o toole g 2017 polysaccharide utilization loci  (Abbott Laboratories)
86
Abbott Laboratories o toole g 2017 polysaccharide utilization loci
a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
O Toole G 2017 Polysaccharide Utilization Loci, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/utility/loci+polysaccharide+utilization/pm42258075-277-15-11
Average 86 stars, based on 1 article reviews
o toole g 2017 polysaccharide utilization loci - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g Immunohistochemical images of tumor sections were examined at 15 days (Ki67 and PCNA, n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.

Journal: Nature Communications

Article Title: Low-intensity pulsed ultrasound-mediated nose-to-brain co-delivery of β-blockers and aPD-L1 enhances glioblastoma immunotherapy

doi: 10.1038/s41467-026-76103-4

Figure Lengend Snippet: a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g Immunohistochemical images of tumor sections were examined at 15 days (Ki67 and PCNA, n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.

Article Snippet: Immunohistochemical staining utilized PCNA (AC058, PCNA Mouse mAb, Abclonal) and Ki67 (A26755PM, Ki67 Rabbit PolymAb®, Abclonal) antibodies, with technical assistance from Nanjing Youmeng Biotechnology Co., Ltd. Tumor sections underwent immunofluorescence staining using a TUNEL assay kit (Beyotime Biotech, Shanghai, China).

Techniques: Sequencing, Magnetic Resonance Imaging, Immunohistochemical staining